The role of inflammation IL-6, TNF-α in type -2 Diabetes Mellitus

Background: Diabetes mellitus is a broad term that refers to a group of metabolic disorders characterized by persistent hyperglycemia, The reason is either a disruption in insulin secretion, varying degrees of insulin resistance, or both. In type 2 diabetes, the pathways leading to β-cell death and malfunction are less clear, but the common denominator seems to be inadequate β-cell insulin production, which often occurs in the context of insulin resistance. An essential indicator of long-term glycemic control and an accurate biomarker for the diagnosis and prognosis of diabetes is HbA1c. The glycation process produces HbA1c, which is a byproduct of Amadori rearrangement and accumulates up in red blood cells. Tumor necrosis factor-alpha (TNF-α) is a cytokine implicated in systemic inflammation that is generated by activated macrophages, CD4+ lymphocytes, natural killer cells, neutrophils, mast cells, eosinophils, and neurons. It usually causes an acute phase response. TNF-α was the first proinflammatory cytokine identified as having a role in the etiology of insulin resistance and type 2 diabetes. T2DM patients have been discovered to have higher levels of circulating inflammatory markers such TNF-α and IL6.In patients with One of the most prevalent metabolic diseases in the world, type 2 diabetes mellitus as a long-term metabolic condition marked by high blood glucose levels that eventually damages the heart, blood vessels, eyes, kidneys, and nerves. T2DM, which accounts for more than 90% of cases of diabetes mellitus, is characterized by tissue insulin resistance (IR), insufficient compensatory insulin secretory response, and insufficient insulin secretion by pancreatic islet β-cells that cause it elevated risk for mortality, CVD and the advancement of type 2 diabetes mellitus. Methods: For this research, 120 blood samples were collected from patients with DM type 2 and 60 volunteers. A sandwich ELISA was used to estimate the serum levels of human TNF-α, and IL-6 and the results were statistically processed in SPSS. Results: Results: The study showed no significant difference (p>0.407) in the mean age among patient groups was (44.51±12.33) years, while the control group was (41.13±10.22) years. The study also examined body weight distribution, finding no significant difference(p->0.32) between patients (24.54±3.44) and the control group (25.11±3.21), serum IL-6 patient groups was (6.44±2.11) while the control group was (1.43±0.32) and TNF-α patient groups was (16.22±2.45) while the control group was (2.34±0.33) in type 2 diabetes mellitus patients compared to the healthy control group. Conclusions: The disease known as T2DM is complex One of the most prevalent metabolic diseases in the world, type 2 diabetes mellitus as a long-term metabolic condition marked by high blood glucose levels association with increase inflammatory biomarkers that leads to developments CVD and kidney failure.